Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016.
Ying-Ming ChiuYi-Peng LuJoung-Liang LanDer-Yuan ChenJung-Der WangPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Our findings indicate that since biologics became available, RA patients have lived longer and had higher lifetime expenditures, which should be monitored and evaluated for cost-effectiveness.